Clinical trials: IDH Wildtype Glioblastoma
Glioblastoma, Glioblastoma, IDH-Wildtype
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
This phase Ib trial tests the safety and side effects of ERAS-801 in treating patients with isocitrate dehydrogenase (IDH) wildtype, epidermal growth factor receptor (EGFR) amplified or mutated grade IV glioblastoma or…
- Conditions
- Glioblastoma, Glioblastoma, IDH-Wildtype, Gliosarcoma, Recurrent Glioblastoma, IDH-Wildtype
- Trial name
- NCT07089641
- Testing
- Biospecimen Collection, Echocardiography Test, EGFR Inhibitor ERAS-801
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Anaplastic Astrocytoma, IDH-Wildtype, Anaplastic Oligoastrocytoma
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
This phase II trial studies how well temozolomide and radiation therapy work in treating patients with IDH wildtype historically lower grade gliomas or non-histological molecular glioblastomas.
- Conditions
- Anaplastic Astrocytoma, IDH-Wildtype, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Diffuse Astrocytoma, IDH-Wildtype
- Trial name
- NCT04623931
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma, IDH Wild-type and STAT3-positive Glioblastoma
Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients
Multicenter, double-blind, placebo-controlled, randomized trial. Patients affected by STAT3 positive newly diagnosed glioblastoma will be eligible.
- Trial name
- STRONG (NCT06964815)
- Testing
- Silibinin as STAT3 inhibitor
- Where
- 16 sites in Italy
- Sponsor
- Istituto Oncologico Veneto IRCCS
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Study of Niacin in Glioblastoma
This is a single institution Phase I-II study to evaluate the tolerability and Maximum Tolerated Dose (MTD) (Phase I) and efficacy (Phase II) of adding Niacin CRT™ to standard first line treatment (concurrent Radiation Therapy…
- Trial name
- NCT04677049
- Testing
- Niacin CRT
- Where
- Canada
- Volunteers
- 59 people
- Sponsor
- AHS Cancer Control Alberta
IDH Family Wildtype, Recurrent Anaplastic Astrocytoma
Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
This phase II trial studies how well laser interstitial thermal therapy and lomustine work in treating patients with glioblastoma or anaplastic astrocytoma that has come back.
- Conditions
- IDH Family Wildtype, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma
- Trial name
- NCT03022578
- Testing
- Laser Interstitial Thermal Therapy, Lomustine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma, IDH-Wildtype
Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma
This phase II trial compares the effect of adding WSD0922-FU to temozolomide versus temozolomide alone in slowing disease progression in patients with Epidermal Growth Factor Receptor (EGFR)-mutant, IDH-wildtype glioblastoma.
- Trial name
- NCT07708961
- Testing
- Archive Sample Retrieval, Biospecimen Collection, Chest Radiography
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4)
A Study of 177Lu-PSMA-617 in People With Gliomas
The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type glioma.
- Conditions
- Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4), Glioblastoma, IDH-wildtype, Diffuse Midline Glioma, H3 K27-Altered
- Trial name
- NCT07223034
- Testing
- Temozolomide, 177Lu-PSMA-617, 68Ga-PSMA-PET scan/ MRI
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioblastoma, IDH-wildtype
Stem Cell Analysis, Omics (Including Immunomics) and Artificial Intelligence in Glioblastoma
The study aims at: 1. Perform a multilayer analysis relying on tight integration of in-depth multi-omics approaches with clinical data to discover immune markers, with attention to age and sex differences, predicting prognosis…
- Trial name
- IPerGlioGEM (NCT05941234)
- Testing
- Biological biomarker analysis
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Astrocytoma, Grade IV
ALBATROSS Study: International Multicenter Study for Prospective Validation of Imaging Biomarkers Calculated at Vascular Habitats of High-grade Gliomas
This Clinical study is framed in the ALBATROSS Project: Clinically validated decision support system based on pixel level Artificial Intelligent models for deciding treatment in glioblastoma.
- Trial name
- ALBATROSS (NCT05229198)
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Juan M Garcia-Gomez
Glioblastoma Multiforme (GBM), Pancreatic Ductal Adenocarcinoma (PDAC)
Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
The goal of this Phase I clinical trial is to evaluate how the imaging drug 203Pb- RMX-VH-PIB distributes in the body and how much radiation different organs receive in patients with glioblastoma multiforme (GBM) or pancreatic…
- Trial name
- RMX-VH (NCT07733674)
- Testing
- 203Pb-RMX-VHPIB injection, SPECT/CT Imaging
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Radiomedix, Inc.
Recurrent Glioblastoma IDH Wildtype
A Clinical Trial of P134 Cells in Recurrent Glioblastoma
This is an open-label, single-arm, dose-escalation and expansion Phase 1/2 clinical trial designed to evaluate the safety, tolerability and efficacy of P134 cells in patients with recurrent glioblastoma, to explore the maximum…
- Trial name
- NCT07318818
- Testing
- P134 cell injection
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma
This is a Phase II trial to evaluate the safety, tolerability, efficacy, and PK/ pharmacodynamic profiles of MT027 injected via ICV in participants with recurrent or progressive IDH-wildtype glioblastoma (WHO 2021 CNS Grade 4)…
- Trial name
- GLIOMAX-101 (NCT07386002)
- Testing
- Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3
- Where
- 4 sites in United States, Taiwan
- Volunteers
- 40 people
- Sponsor
- T-MAXIMUM Pharmaceutical Inc
Glioblastoma, Diffuse Glioma
Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma
Multicenter, open-label, single-arm Phase 1/2 study on the safety and efficacy of the combination of NMS-03305293 and temozolomide (TMZ) in adult patients with diffuse gliomas (Phase 1) and isocitrate dehydrogenase (IDH) wild…
- Trial name
- NCT04910022
- Testing
- NMS-03305293, Temozolomide
- Where
- 18 sites in United States, Italy and 3 more
- Volunteers
- 150 people
- Sponsor
- Nerviano Medical Sciences
Recurrent Glioblastoma, IDH-Wildtype
Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma
This phase II trial compares the safety, side effects and effectiveness of atezolizumab with tiragolumab to atezolizumab alone in treating patients with glioblastoma that has come back after a period of improvement (recurrent).
- Trial name
- NCT06328036
- Testing
- Atezolizumab, Biospecimen Collection, Magnetic Resonance Imaging
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, Astrocytoma, IDH-Mutant, Grade 4
Extensive Resection of Malignant Brain Tumors Using Advanced Imaging Techniques
Rationale: Patients with IDH-wildtype glioblastoma or grade IV IDH-mutant astrocytoma have a very poor prognosis despite standard treatment consisting of surgery, radiotherapy, and chemotherapy.
- Trial name
- NEXTFRONTIER (NCT06623565)
- Testing
- Multimodal image-guided resection
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Amsterdam UMC, location VUmc
Glioblastoma, IDH-Wildtype, WHO Grade 4 Glioma
Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma
This clinical trial studies whether continuous glucose monitoring (CGM) can be used to help patients with glioblastoma manage their blood sugar (glucose) levels and improve survival.
- Trial name
- NCT07091864
- Testing
- Best Practice, Biospecimen Collection, Dietary Intervention
- Where
- 3 sites in United States
- Volunteers
- 116 people
- Sponsor
- Mayo Clinic
Astrocytoma, IDH-Mutant, Grade 4, Diffuse Glioma
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden
This phase II trial studies the effect of immunotherapy drugs (ipilimumab and nivolumab) in treating patients with glioma that has come back (recurrent) and carries a high number of mutations (mutational burden).
- Conditions
- Astrocytoma, IDH-Mutant, Grade 4, Diffuse Glioma, Glioblastoma, IDH-Wildtype, Secondary Glioblastoma
- Trial name
- NCT04145115
- Testing
- Ipilimumab, Magnetic Resonance Imaging, Nivolumab
- Where
- 414 sites in United States, Puerto Rico
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
IDH-Wildtype Glioblastoma, Glioblastoma (GBM)
The Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of Glioblastoma
The body's biological functions follow a circadian rhythm, meaning that individual biological functions in the body change over a 24-hour cycle.
- Trial name
- TMZ-CHRONO (NCT06850766)
- Testing
- Morning administration of TMZ, Evening administration of TMZ
- Where
- 2 sites in Canada
- Volunteers
- 50 people
- Sponsor
- Ottawa Hospital Research Institute
Glioblastoma, Glioblastoma Multiforme
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
Primary brain cancer kills up to 10,000 Americans a year. These brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination.
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioma, Malignant, GBM
- Trial name
- NCT05271240
- Testing
- Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation, Temozolomide and Radiation Alone
- Where
- United States
- Volunteers
- 432 people
- Sponsor
- Northwell Health
Glioma, Glioblastoma
Sub-lobectomy for IDH Wild-type and TERT Promoter Mutant Glioblastoma
Glioblastoma is recognized as the most common and aggressive form of primary malignant brain tumor, with treatment options that are limited and prognosis that is extremely poor, showing median progression-free survival of 12…
- Trial name
- NCT06368934
- Testing
- sub-lobectomy, imaging total resection
- Where
- China
- Volunteers
- 326 people
- Sponsor
- Huashan Hospital